

Repeat associated non-AUG (RAN) proteins in rare and common diseases: molecular insights and therapeutic opportunities

Lisa E.L. Romano¹, Monica Banez Coronel¹, Tao Zu¹, Lien Nguyen¹, Shu Guo¹, Beverly L. Davidson^{2,3}, [Laura P.W. Ranum](#)¹

¹Department of Molecular Genetics and Microbiology, Center for NeuroGenetics and the Genetics Institute, McKnight Brain Institute and the Fixel Institute for Neurological Diseases, College of Medicine, University of Florida, Gainesville, FL;

²The Children's Hospital of Philadelphia, Center for Cellular and Molecular Therapeutics, Philadelphia, PA;³University of Pennsylvania, Perelman School of Medicine, Department of Pathology and Laboratory Medicine, Philadelphia, PA

Parkinson's disease (PD) is the second most common neurodegenerative disease and the most common movement disorder characterized by motor impairments resulting from midbrain dopamine (DA) neuron loss. Mutations in LRRK2 cause genetic PD and contribute to sporadic PD. We recently generated the human LRRK2 G2019S transgenic mouse model that displays PD-like movement impairment. Here, we used LRRK2-G2019S transgenic mouse model to investigate abnormalities in arteriolar cerebral blood volume (CBVa) in various brain regions using the inflow-based vascular-space-occupancy (iVASO) MRI technique. CBVa was measured in the substantia nigra (SN), olfactory cortex and prefrontal cortex. Compared to non-transgenic mice, G2019S-LRRK2 mice at 9 months of age showed decreased CBVa in the SN, but increased CBVa in olfactory and prefrontal cortex in both male and female groups, whereas WT-LRRK2 mice showed no change in CBVa in the SN (male and female), the olfactory (female) and prefrontal (female) cortex, but a slight increase in CBVa in the olfactory and prefrontal cortex in the male group only. Alterations in the blood volume of small arteries and arterioles (CBVa) were detected in the G2019S-LRRK2 mouse model of PD. The opposite changes in CBVa in the SN and the cortex indicate that PD pathology may have differential effects in different brain regions. Our results suggest the potential value of CBVa as a marker for clinical PD studies.

Sponsored By: grants from NIH, DOD and the National Ataxia Foundation

Presenter Name and contact information:

Laura Ranum, Ph.D., Distinguished Professor
Center for NeuroGenetics and Department of Molecular Genetics and Microbiology
University of Florida
Gainesville, FL, USA
Email: ranum@ufl.edu